Lung cancer: potential targets for immunotherapy

Lancet Respir Med. 2013 Sep;1(7):551-63. doi: 10.1016/S2213-2600(13)70159-0. Epub 2013 Aug 23.

Abstract

Lung cancer is the most common cause of cancer-related mortality worldwide and a therapeutic challenge. Recent success with antibodies blocking immune checkpoints in non-small-cell lung cancers (NSCLC) highlights the potential of immunotherapy for lung cancer treatment, and the need for trials of combination regimens of immunotherapy plus chemotherapy that lead to immunogenic cell death. Here, we review the development of immunogenic cytotoxic compounds, vaccines, and antibodies in NSCLC, in view of their integration into personalised oncology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens, Neoplasm / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Trials as Topic
  • Humans
  • Immunity, Cellular / immunology
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy / methods*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / therapy*
  • Molecular Targeted Therapy / methods
  • Tumor Escape / immunology
  • Tumor Microenvironment / immunology

Substances

  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Cancer Vaccines
  • Immunologic Factors
  • Immunosuppressive Agents